NCT06406465
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity treatment 2 not_yet_recruiting NCT04525638
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours treatment 2 recruiting NCT03110978
Stereotactic Body Radiation Therapy with or Without Nivolumab in Treating Patients with Stage I-IIA or Recurrent Non-small Cell Lung Cancer treatment 2 active_not_recruiting NCT03728361
Nivolumab and Temozolomide in Treating Patients with Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer treatment 2 active_not_recruiting NCT03074513
Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors treatment 2 active_not_recruiting NCT04701307
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas treatment 2 active_not_recruiting NCT02236910
An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours No drug interventions treatment 2 active_not_recruiting NCT03591731
Nivolumab +/- Ipilimumab in Patients with Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) treatment 2 active_not_recruiting NCT04471727
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) treatment 1 / 2 recruiting NCT05619744
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas treatment 1 recruiting NCT04069299
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract Not Available Not Available recruiting NCT05237934
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) No drug interventions Not Available Not Available recruiting NCT06041516
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas No drug interventions treatment 1 recruiting NCT06333314
Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI treatment 2 recruiting NCT05978284
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma No drug interventions treatment 1 / 2 recruiting NCT00363051
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy treatment 2 completed NCT01642251
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer treatment 1 / 2 completed NCT03837977
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma treatment 2 active_not_recruiting NCT03278405
Avelumab in G3 NEC treatment 1 / 2 completed NCT02754297
Personalized PRRT of Neuroendocrine Tumors treatment 2 active_not_recruiting NCT01876771
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours treatment 2 recruiting NCT03168607
Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma treatment 2 unknown_status NCT05262556
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas treatment 1 active_not_recruiting NCT05420636
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET treatment 2 recruiting NCT05396118
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients diagnostic 2 enrolling_by_invitation NCT04705519
Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma treatment 2 unknown_status NCT02687958
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin treatment 2 active_not_recruiting NCT00019786
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases treatment 2 completed NCT02970786
Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans No drug interventions diagnostic 1 unknown_status NCT04464122
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) Not Available Not Available recruiting NCT04325425
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary treatment 2 recruiting NCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) No drug interventions Not Available Not Available recruiting NCT04985357
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs No drug interventions Not Available Not Available not_yet_recruiting NCT03012620
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types treatment 2 completed NCT01396382
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer No drug interventions diagnostic 2 completed NCT05627427
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy treatment 2 recruiting NCT00113360
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma treatment 2 completed NCT02688894
The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S] No drug interventions Not Available Not Available recruiting NCT03168594
Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma treatment 2 terminated NCT00511862
TheraSphere for the Treatment of Liver Metastases No drug interventions treatment 2 completed NCT05747729
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. treatment 1 / 2 not_yet_recruiting NCT00663429
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma treatment 2 completed NCT00926640
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers treatment 1 completed NCT03079440
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors treatment 2 completed NCT06369181
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC No drug interventions Not Available Not Available recruiting NCT02487095
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers treatment 1 / 2 active_not_recruiting NCT00003514
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy treatment 2 withdrawn NCT05113355
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm treatment 2 recruiting NCT02936323
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers treatment 1 / 2 completed NCT02038738
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors diagnostic 1 / 2 unknown_status NCT04268121
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas treatment 2 recruiting NCT03290079
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors treatment 2 completed NCT01886287
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome treatment 2 terminated NCT06577987
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies No drug interventions treatment 1 recruiting NCT03600233
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors treatment 2 active_not_recruiting NCT06400654
PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC No drug interventions Not Available Not Available recruiting NCT04583605
The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors No drug interventions Not Available Not Available unknown_status NCT05709171
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms diagnostic 2 enrolling_by_invitation NCT03901378
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma treatment 2 withdrawn NCT03517488
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors treatment 1 completed NCT02250885
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors treatment 2 completed NCT03037385
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors treatment 1 / 2 completed NCT02205515
An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis treatment 1 / 2 completed NCT00353015
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract treatment 2 completed NCT00607113
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma treatment 2 completed NCT06242119
Clinical Application of the J-PET Scanner Prototype No drug interventions Not Available Not Available recruiting NCT00388063
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma treatment 2 completed NCT04488263
Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s No drug interventions Not Available Not Available terminated NCT03647163
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors treatment 1 / 2 recruiting NCT05076786
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma treatment 2 recruiting NCT01121939
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers treatment 2 completed NCT00004922
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors treatment 2 completed NCT02315625
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery treatment 2 terminated NCT06440057
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. No drug interventions treatment 1 / 2 not_yet_recruiting NCT01879657
68-Ga-DOTATATE PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs) No drug interventions diagnostic Not Available completed NCT06372626
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. treatment 1 / 2 recruiting NCT00193531
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma treatment 2 completed NCT03387592
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas treatment 2 unknown_status NCT02270567
RegisterNET - A Registry for Neuroendocrine Tumors in the USA No drug interventions Not Available Not Available enrolling_by_invitation NCT03834701
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms No drug interventions treatment Not Available completed NCT02248012
Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) treatment 2 completed NCT03279614
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma No drug interventions treatment 2 unknown_status NCT03858855
Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment No drug interventions supportive_care Not Available completed NCT05064150
Neuroendocrine Tumors - Patient Reported Outcomes No drug interventions Not Available Not Available enrolling_by_invitation NCT04524208
A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 treatment 2 active_not_recruiting NCT02695459
Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin treatment 2 unknown_status NCT02457273
Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients treatment 2 completed NCT04122911
Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas treatment 2 completed NCT01203306
Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors treatment 2 unknown_status NCT05337735
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers treatment 2 suspended NCT02820857
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer treatment 2 active_not_recruiting